Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NUN-004 Phase 2 randomized placebo-controlled study in amyotrophic lateral sclerosis
ACTRN12626001318370Phase 2Not yet recruiting
- Sponsor
- NuNerve
- Start
- Nov 2026
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in amyotrophic lateral sclerosis (ALS) comparing NUN-004 randomized arm with Placebo randomized arm (2 arms). Primary endpoints: Change in disease progression, Safety of NUN-004 and 1 more. Planned start Nov 2026; status: not yet recruiting.
02
Drugs
mEphA4-Fc
03
Conditions
amyotrophic lateral sclerosis (ALS)
Beyond the preview
Go deeper on ACTRN12626001318370.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12626001318370.